Latest filing published 08 Mar 2022 for Sarepta Therapeutics, Inc., €83k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
William Ciambrone: trading record in brief
William Ciambrone (senior executive) discloses dealings in Sarepta Therapeutics, Inc. to SEC (Form 4). We count 3 filings; the first trade dates from 3 March 2021 and the latest from 7 March 2022.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The latest filing, published on 8 March 2022, reports a share grant in Sarepta Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to William Ciambrone
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,160 shares@ US$79.20100.0% of flowCommon StockSEC:0001209191-22-017345:0
1 of 1 declaration
